64380-178 : Accolate 20 mg Oral Tablet, Film Coated
NDC: | 64380-178 |
Labeler: | Strides Pharma Science Limited |
Product Type: | Human Prescription Drug |
Drug Name: | Accolate |
Dosage Form: | Oral Tablet, Film Coated |
Application #: | NDA020547 |
Rev. Date: |
NDC Package Codes:
- 64380-178-01: 60 TABLET, FILM COATED IN 1 BOTTLE (64380‑178‑01)
Active Ingredients:
- Zafirlukast
Dosage Strength:
- 20 mg
Pharmaceutical Classes:
- Cytochrome P450 2C9 Inhibitors [MoA]
- Leukotriene Receptor Antagonist [EPC]
- Leukotriene Receptor Antagonists [MoA]
Related Products:
Based on records with the same trade name.- 64380-177 Accolate 10 mg Oral Tablet, Film Coated by Strides Pharma Science Limited
- 0310-0401 Accolate 10 mg Oral Tablet by Astrazeneca Pharmaceuticals Lp
- 0310-0402 Accolate 20 mg Oral Tablet by Astrazeneca Pharmaceuticals Lp
- 49884-010 Accolate 10 mg Oral Tablet, Film Coated by Par Pharmaceutical Inc.
- 49884-011 Accolate 20 mg Oral Tablet, Film Coated by Par Pharmaceutical Inc.
- 49884-589 Accolate 10 mg Oral Tablet, Coated by Par Pharmaceutical Inc.
- 49884-590 Accolate 20 mg Oral Tablet, Coated by Par Pharmaceutical Inc.
- 53808-0203 Accolate 20 mg Oral Tablet by State of Florida Doh Central Pharmacy
NDC QR Code
Scan the QR code below to easily reference this data in the future:< Prev: 64380-177Next: 64380-179 >
Related Discussions:
Accolate availability
Are there any lower cost substitutes for Accolate? Anyone know when the patent on it runs out? ## I have received no rep... 1 reply
Are there any lower cost substitutes for Accolate? Anyone know when the patent on it runs out? ## I have received no rep... 1 reply
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.